Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
08 Maio 2023 - 8:06AM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced a poster presentation on
OP-1250, the Company’s complete estrogen receptor (ER) antagonist
(CERAN) and selective ER degrader (SERD) in development for the
treatment of metastatic breast cancer, at the upcoming ESMO Breast
Cancer Annual Congress 2023 taking place May 11-13, 2023, in
Berlin, Germany.
Details of the ESMO Breast Cancer Annual Congress 2023
poster presentation are:
Title: |
A
phase 1b/2 study of OP-1250, an oral complete estrogen receptor
(ER) antagonist (CERAN) and selective ER degrader (SERD) with
palbociclib in patients (pts) with advanced or metastatic
ER-positive, HER2-negative breast cancer (MBC) (ID 406) |
Presentation
#: |
202P |
Date: |
Friday, May 12, 2023 |
Time: |
12:15 p.m. CEST (6:15 a.m.
EDT) |
A copy of the poster will be made available on Olema’s website
under the Science section when it is presented at the congress.
Abstracts for the posters can be found on the ESMO Breast Cancer
Annual Congress website here.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, OP-1250, is a proprietary,
orally available small molecule with dual activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated both as a
single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been
granted FDA Fast Track designation for the treatment of ER+/HER2-
metastatic breast cancer that has progressed following one or more
lines of endocrine therapy with at least one line given in
combination with a CDK4/6 inhibitor. Olema is headquartered in San
Francisco and has operations in Cambridge, Massachusetts.
IR Contact:Shane Kovacs, Chief Operating and
Financial Officer ir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024